In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $27. The company’s shares closed on Friday at $5.42.
Tanner said:
“: We reiterate our Overweight rating and $27 PT for TXMD stock. FDA approval of TX-001, together with the licensure of Imvexxy, would represent a major corporate achievement, as we believe both drugs will become important treatments for gynecologic conditions that afflict large populations of menopausal women. Dissatisfaction with vulvar vaginal atrophy (VVA) treatments is well documented, and we view Imvexxy as differentiated from other options by its low estrogen doses and gel cap formulation. If approved, TX-001 would be the first FDA-regulated estrogen plus progesterone (E+P) product. Uptake could significantly benefit from increased oversight of drug compounding, in our view.”
According to TipRanks.com, Tanner is a 2-star analyst with an average return of 0.6% and a 43.8% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Evofem Biosciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $20.33 average price target, implying a 275.1% upside from current levels. In a report issued on October 2, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.22 million. In comparison, last year the company had a GAAP net loss of $14.66 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
